This case report describes a unique presentation of a metastasis from a neuroendocrine carcinoma
of the lung, presenting itself as a palpable tumour of the testis.
In our case, the liver metastasis had a nested growth pattern of cells with a neuroendocrine appearance, and it expressed synaptophysin, leading to the original diagnosis of metastatic neuroendocrine carcinoma
Merkel cell carcinoma Paraffin-embedded 6 (30) 9 (45) Frozen tissue 12 (100) 12 (100) Other neuroendocrine carcinomas
Paraffin-embedded 0 0 Frozen tissue 0 0 * Non-Merkel cell carcinoma high-grade neuroendocrine carcinomas
were 5 small-cell lung carcinomas, 3 well-differentiated intestinal carcinomas, and 1 high-grade neuroendocrine carcinoma
of the cervix.
Criteria are proposed not only for adenocarcinoma but also for squamous cell carcinoma and tumors that in resection specimens might be classified as large cell carcinoma, large cell neuroendocrine carcinoma
, adenosquamous carcinoma, and sarcomatoid carcinoma (Tables 1 and 2), because previous WHO classifications never addressed criteria for these tumors in small biopsies and cytology specimens.
The differential diagnosis of SCCB is quite broad and includes poorly differentiated urothelial carcinoma, poorly differentiated squamous cell carcinoma, lymphoma, lymphoepithelioma-like carcinoma, plasmacytoid carcinoma, large cell neuroendocrine carcinoma
, SCLC metastatic to the bladder or SCC of the prostate invading into the bladder.
Are UEC and Neuroendocrine Carcinoma
the Same or Different?
Therapeutics - Pipeline Assessment and Market Forecast to 2019 report is an essential source of information and analysis on the global Neuroendocrine carcinoma
We present a case of gastric composite carcinoma composed of adenocarcinoma and neuroendocrine carcinoma
that appeared to arise from a background of lymphocytic gastritis.
Among these was a patient with small-cell cervical neuroendocrine carcinoma
who had an unconfirmed PR; she previously had received two other treatment regimens for her cancer.
GlobalData has estimated that the global neuroendocrine carcinoma
therapeutics market was worth $127m in 2011 and is forecast to grow at Compound Annual Growth Rate (CAGR) of 17.
SUTENT is also approved for the treatment of unresectable well-differentiated advanced and/or metastatic pancreatic neuroendocrine carcinoma
in the Philippines, Switzerland, Colombia and Korea.
Surgical pathology reported a primary neuroendocrine carcinoma
of the pancreas (insulinoma) and metastatic neuroendocrine carcinomas
to the liver.